Signature Equity Partners’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
Other funds holding NVS
Signature Equity Partners's NVS Position: Q2 2026 in Review
Signature Equity Partners increased its Novartis (NVS) stake by 5.3% in Q2 2026, buying an estimated $1.8K and bringing the position to 240 shares worth $37.6K. The position accounts for 0.02% of the portfolio, ranked #495.
Signature Equity Partners first reported a position in NVS in Q4 2025 and has held it in 3 quarters since. The position peaked at $37.6K in Q4 2025. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Signature Equity Partners held 240 shares of Novartis worth $37.6K as of Q2 2026.
- Signature Equity Partners bought 12 Novartis shares in Q2 2026, an estimated $1.8K.
- Novartis made up 0.02% of Signature Equity Partners's portfolio in Q2 2026, its #495 holding.
- Signature Equity Partners first reported a position in Novartis in Q4 2025 and has held it in 3 quarters since.
- Signature Equity Partners's Novartis position peaked at $37.6K in Q4 2025.
- 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.